|Bid||178.19 x 1100|
|Ask||178.20 x 800|
|Day's Range||177.64 - 179.08|
|52 Week Range||153.56 - 201.23|
|PE Ratio (TTM)||66.19|
|Forward Dividend & Yield||5.28 (2.99%)|
|1y Target Est||N/A|
Merck & Company (MRK) reported revenue of $10.0 billion in Q1 2018 compared to $9.4 billion in Q1 2017, which reflected a ~6% rise YoY (year-over-year) and a ~4% fall sequentially. In Q1 2018, Merck saw a ~2% positive impact from foreign exchange.
How Is Alnylam Pharmaceuticals Positioned in 2018? Since the beginning of 2018, the stock price of Alnylam Pharmaceuticals has dropped from $130 levels to $100 as of May 21. Overall, Alnylam Pharmaceuticals has fallen 24%.
Kezar Life Sciences Inc., which would trade on the NASDAQ exchange as "KZR," is the fifth Bay Area life sciences company this year to file for an IPO, and it's indicative of the ability founders have to go public early on in the process of building a drug development company. Spun out of Amgen Inc. with small molecules from the plate of the former Onyx Pharmaceuticals Inc., the South San Francisco company is developing drugs for autoimmune diseases, where the immune system starts attacking healthy cells. Its first drug, KZR-616, is enrolling patients in a mid-stage Phase Ib/II study in lupus and lupus nephritis, or inflammation in the kidney.
In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.
Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases. The chart below compares Ionis’s revenue and EPS since Q1 2017. In the first quarter, Ionis’s revenue rose ~24.7% year-over-year to $144.4 million from $115.8 million.
How Is Alnylam Pharmaceuticals Positioned in 2018? Alnylam Pharmaceuticals (ALNY) is a global biopharmaceutical company focused on developing RNA interference-based novel therapeutics. Alnylam is harnessing this pathway to develop a new class of innovative medicines called RNAi therapeutics.
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, and other biotechnology assets traded slightly higher Wednesday after the U.S. House of Representatives on Tuesday passed “right to try” legislation. IBB tracks the Nasdaq Biotechnology Index and holds nearly 160 stocks.
A month ago, Pfizer Inc. (NYSE:PFE) felt the sting of a somewhat surprising disappointment. Its biosimilar version of Herceptin, the popular breast cancer drug from Roche Holding AG (OTCMKTS:RHHBY), was rejected by the FDA.Biosimilar drugs are nearly-identical copies of a competitor’s product. It was a blow not just because Herceptin generated sales of more than $7 billion last year, but because it put the viability of Pfizer’s entire biosimilar program into question.
Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.
Last week, the Trump administration, via secretary of health and human services, Alex Azar, proposed that drug makers be required to include the list prices of drugs in all direct-to-consumer ads. In addition, payers are providing support for the prices being set. Just last week, Amgen announced that the price of its new migraine drug, Aimovig, would be set at $6,900 per year.
Amgen trades at a premium to biotech companies Celgene and Biogen, but analysts are worried its pipeline contains fewer blockbuster opportunities.
Roche’s (RHHBY) MabThera/Rituxan reported revenues of 1.7 billion Swiss francs in the first quarter compared to 1.9 billion Swiss francs in the first quarter of 2017, which reflected a decline of ~8% YoY (year-over-year) on constant exchange rate basis.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 21) AstraZeneca plc (ADR) (NYSE: AZN ) (FDA approved its ...
Lisa DeLeonardo set a Google alert so she would know exactly when the first in a new class of migraine drugs was approved. It happened Thursday, when the U.S. Food and Drug Administration approved Amgen and Novartis’ application for erenumab, whose brand name is Aimovig. It’s an injectable drug touted as the first treatment designed specifically to prevent migraines, and is expected to be available to patients within a week for an annual price of $6,900.
Northern California showed itself to be an accommodating and receptive host for the 13th annual Amgen Tour of California.
Migraine is one of the top 10 causes of years lived with disability globally. With Aimovig receiving FDA approval for treatment of migraine, investors' attention is on future regulatory decisions.
After a heated week of litigation battles, CBS on Thursday proceeded with a board meeting it had scheduled to vote on whether to dilute the voting power of National Amusements Inc., a company controlled by Shari Redstone. This came after a court decision that said CBS could not prevent Redstone from changing CBS's bylaws to prevent that from occurring. All of which means CBS directors and Redstone will be back in court soon to fight over voting control, with Redstone pushing to combine CBS with Viacom, unless of course, both sides instead consider the option to auction the media company.
One Wall Street analyst predicts the anti-migraine category could be a $1 billion to $2 billion business over the next five years. Michael Yee, managing director at Jefferies, expects others companies to get into the migraine treatment sector. The anti-migraine drug Aimovig from Amgen AMGN and Novartis NVS could become a $1 billion to $2 billion business over the next five years, said a Wall Street analyst.
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.